Published in:
01-08-2014 | Hepatobiliary Tumors
Impact of Viral Hepatitis on Outcomes after Liver Resection for Hepatocellular Carcinoma: Results from a North American Center
Authors:
Jonghun J. Lee, BSc, Peter T. W. Kim, MD, MSc, FRCSC, Sandra Fischer, MD, FRCPC, Scott Fung, MD, FRCPC, Steven Gallinger, MD, MSc, FRCSC, Ian McGilvray, MD, PhD, FRCSC, Carol-anne Moulton, MD, PhD, FRCSC, Alice C. Wei, MD, MSc, FRCSC, Paul D. Greig, MD, FRCSC, Sean P. Cleary, MD, MSc, MPH, FRCSC
Published in:
Annals of Surgical Oncology
|
Issue 8/2014
Login to get access
Abstract
Background
Hepatitis B (HBV) and hepatitis C (HCV) are well-recognized risk factors for hepatocellular carcinoma (HCC). The characteristics and clinical outcomes of HCC arising from these conditions may differ. This study was conducted to compare the outcomes of HCC associated with HBV and HCV after liver resection.
Methods
Of 386 liver resections for HCC performed between July 1992 and April 2011, 181 patients had HBV and 74 patients had HCV. Patients with HBV/HCV coinfections (n = 20), non-HBV/HCV etiology (n = 94), and postoperative death within 3 months (n = 17) were excluded. Patient, tumor characteristics, and perioperative and oncologic outcomes were compared between patients with HBV and HCV.
Results
The patients with HBV had better overall survival (OS) than patients with HCV (68 vs. 59 months, p = 0.03); however, there was no difference in recurrence-free survival (RFS) between the groups (44 vs. 45 months, p = 0.1). The factors predictive of OS based on multivariate analyses included: vascular invasion [p < 0.01, hazard ratio (HR) = 3.4], Child-Pugh Score (p < 0.01, HR = 4.8), and underlying liver disease (HCV vs HBV) (p = 0.01, HR = 1.9). Vascular invasion and tumor number (p < 0.01, HR = 2.3 and p < 0.01, HR = 2.1) were independent predictors of RFS.
Conclusions
OS but not RFS after liver resection for HCC is better in patients with HBV than HCV. This survival advantage for HBV patients may be due to differences in tumor biology and outcomes after disease recurrence.